Marine-derived n-3 fatty acids therapy for stroke

Campano, Celia Gabriela Alvarez; MacLeod, Mary Joan; Aucott, Lorna; Thiès, Frank

doi:10.1002/14651858.cd012815

Cited by 7 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bempedoic acid is a first-in class therapy adenosine triphosphate-citrate lyase 54 inhibitor that reduces LDL-C levels by 15% to 25% depending on the type and dose of background statin therapy and is associated with fewer muscle-related adverse effects. 33,34 It is also available in a combination product with ezetimibe that reduces LDL-C levels by ∼35%.…”

Section: Treatmentmentioning

confidence: 99%

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Virani,

Newby,

Arnold

et al. 2023

Circulation

279

112

View full text Add to dashboard Cite

AIM The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new evidence since the “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease” and the corresponding “2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease.” Methods A comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Structure This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost–value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.

show abstract

Section: Treatmentmentioning

confidence: 99%

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Virani,

Newby,

Arnold

et al. 2023

Circulation

279

112

View full text Add to dashboard Cite

show abstract

“…Some metabolites have been reported to play a critical role in the development of cardiac hypertrophy and heart failure by regulating inflammatory reaction [19][20][21] . Recently, clinical trials showed that omega-3 FA supplementation reduced cardiovascular events [22][23][24][25][26] , but the underlying molecular mechanisms remain unknown.…”

mentioning

confidence: 99%

Omega-3 fatty acid prevents the development of heart failure by changing fatty acid composition in the heart

Toko

Morita

Katakura

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Some clinical trials showed that omega-3 fatty acid (FA) reduced cardiovascular events, but it remains unknown whether omega-3 FA supplementation changes the composition of FAs and their metabolites in the heart and how the changes, if any, exert beneficial effects on cardiac structure and function. To clarify these issues, we supplied omega-3 FA to mice exposed to pressure overload, and examined cardiac structure and function by echocardiography and a proportion of FAs and their metabolites by gas chromatography and liquid chromatography-tandem mass spectrometry, respectively. Pressure overload induced cardiac hypertrophy and dysfunction, and reduced concentration of all FAs’ components and increased free form arachidonic acid and its metabolites, precursors of pro-inflammatory mediators in the heart. Omega-3 FA supplementation increased both total and free form of eicosapentaenoic acid, a precursor of pro-resolution mediators and reduced free form arachidonic acid in the heart. Omega-3 FA supplementation suppressed expressions of pro-inflammatory cytokines and the infiltration of inflammatory cells into the heart and ameliorated cardiac dysfunction and fibrosis. These results suggest that omega-3 FA-induced changes of FAs composition in the heart have beneficial effects on cardiac function via regulating inflammation.

show abstract

“…The Supplementation en Folates et Omega‐3 trial found no effect of post‐stroke supplementation with 600 mg eicosapentaenoic and docosahexaenoic acids (2:1 ratio) on health‐related quality of life, measured by the Medical Outcomes Study 36‐Item Short‐Form Health Survey [30]. Two small studies observed non‐significant protective effects of n‐3 fatty acid supplementation on functional outcomes, as measured by the GOSE scale, the Barthel Index, and the Rivermead Mobility Index [31,32], although the quality of the evidence from these studies was judged to be of very low in a recent Cochrane review [33]. In addition, these studies only assessed post‐stroke supplementation with n‐3 fatty acids and could not assess how supplementation prior to the event may influence outcomes.…”

Section: Discussionmentioning

confidence: 99%

Effect of vitamin D and/or omega‐3 fatty acid supplementation on stroke outcomes: A randomized trial

Rist

Buring

Cook

et al. 2020

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose Among stroke patients, low serum 25‐hydroxyvitamin D predicts poor outcomes. In mice, higher omega‐3 (n‐3) fatty acid intake diminishes brain damage after stroke. In this study, we tested whether vitamin D or n‐3 fatty acids supplementation prior to stroke reduces the risk of functional limitations and physical disability after stroke. Methods We used data from VITAL (the VITamin D and OmegA‐3 TriaL) which randomized middle‐aged and older men and women without cardiovascular disease to vitamin D3 (2000 IU/day) and/or marine n‐3 fatty acids (1 g/day) and followed them for incident stroke events. Individuals experiencing a non‐fatal stroke were mailed questionnaires assessing functional limitations (the physical performance scale adapted from Nagi) and physical disability (the modified Katz Activities of Daily Living and Rosow‐Breslau Functional Health scales). We used logistic regression to analyze associations between randomized treatment and limitations on each scale. Results A total of 290 individuals experienced their first stroke during the trial, of whom 197 stroke survivors completed the stroke outcomes questionnaire a median of 1.4 years after diagnosis. We observed no associations between randomized treatment to vitamin D and functional limitations (odds ratio [OR] 1.01, 95% confidence interval [CI] 0.52, 1.97) or physical disability (Rosow‐Breslau scale: OR 0.92, 95% CI 0.50, 1.67; Katz scale: OR 1.03, 95% CI 0.31, 3.42). Those randomized to n‐3 fatty acids had a non‐significantly lower risk of functional limitations (OR 0.55, 95% CI 0.28, 1.09) and physical disability (Rosow‐Breslau scale: OR 0.56, 95% CI 0.31, 1.02; Katz sclae: OR 0.32, 95% CI 0.50, 1.67). Conclusion Vitamin D or omega‐3 fatty acid supplementation prior to stroke did not result in significantly improved post‐stroke outcomes.

show abstract

Marine-derived n-3 fatty acids therapy for stroke

Abstract: This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of marine-derived n-3 fatty acids administration on functional outcomes and dependence in people with stroke. 1 Marine-derived n-3 fatty acids therapy for stroke (Protocol)

Cited by 7 publications

References 46 publications

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Omega-3 fatty acid prevents the development of heart failure by changing fatty acid composition in the heart

Effect of vitamin D and/or omega‐3 fatty acid supplementation on stroke outcomes: A randomized trial

Contact Info

Product

Resources

About